Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
View Patent ↗A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
1. An oral dosage form comprising:
(A) a core comprising:
(a) from about 5 mg to about 20 mg of doxylamine and/or a pharmaceutically acceptable salt thereof; and
(b) from about 5 mg to about 20 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof;
(B) an enteric coating substantially surrounding the core; and
(C) one or more outer coatings substantially surrounding the enteric coating, the one or more outer coatings comprising:
(a) from about 5 mg to about 20 mg of doxylamine and/or a pharmaceutically acceptable salt thereof; and
(b) from about 5 mg to about 20 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof.
2. The oral dosage form of claim 1 , wherein the core comprises about 10 mg of doxylamine and/or a pharmaceutically acceptable salt thereof.
3. The oral dosage form of claim 1 , wherein the core comprises about 10 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof.
4. The oral dosage form of claim 1 , wherein the one or more outer coatings comprise about 10 mg of doxylamine and/or a pharmaceutically acceptable salt thereof.
5. The oral dosage form of claim 1 , wherein the one or more outer coatings comprise about 10 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof.
6. The oral dosage form of claim 1 , wherein the core comprises doxylamine succinate.
7. The oral dosage form of claim 1 , wherein the one or more outer coatings comprise doxylamine succinate.
8. The oral dosage form of claim 2 , wherein the core comprises doxylamine succinate.
9. The oral dosage form of claim 4 , wherein the one or more outer coatings comprise comprises doxylamine succinate.
10. The oral dosage form of claim 1 , wherein the core comprises pyridoxine hydrochloride.
11. The oral dosage form of claim 1 , wherein the one or more outer coatings comprise pyridoxine hydrochloride.
12. The oral dosage form of claim 3 , wherein the core comprises pyridoxine hydrochloride.
13. The oral dosage form of claim 5 , wherein the one or more outer coatings comprise pyridoxine hydrochloride.
14. The oral dosage form of claim 1 , wherein the one or more outer coatings comprise a first outer coating and a second outer coating.
15. The oral dosage form of claim 14 , wherein the first outer coating comprises the doxylamine and/or pharmaceutically acceptable salt thereof, and the second outer coating comprises the pyridoxine and/or a pharmaceutically acceptable salt thereof.
16. The oral dosage form of claim 1 , comprising:
(A) a core comprising:
(a) about 10 mg of doxylamine succinate; and
(b) about 10 mg of pyridoxine hydrochloride;
(B) an enteric coating substantially surrounding the core; and
(C) one or more outer coatings substantially surrounding the enteric coating, the one or more outer coatings comprising:
(a) about 10 mg of doxylamine succinate; and
(b) about 10 mg of pyridoxine hydrochloride.
17. The oral dosage form of claim 1 , comprising:
(A) a core comprising:
(a) about 10 mg of doxylamine succinate; and
(b) about 10 mg of pyridoxine hydrochloride;
(B) an enteric coating substantially surrounding the core; and
(C) two outer coatings substantially surrounding the enteric coating, the two outer coatings comprising:
(a) a first outer coating comprising about 10 mg of pyridoxine hydrochloride; and
(b) a second outer coating comprising about 10 mg of doxylamine succinate.
18. A method for alleviating the symptoms of nausea and vomiting in a mammal, said method comprising administering the oral dosage form of claim 1 to a mammal in need thereof.
19. A method for alleviating the symptoms of nausea and vomiting of human pregnancy, said method comprising administering the oral dosage form of claim 1 to a pregnant human female in need thereof.